Korenberg Matthew E 4

What Happened

• Matthew E. Korenberg, Chief Financial Officer and Treasurer of Palvella Therapeutics (PVLA), received a grant of 44,123 derivative shares/options on Feb 5, 2026. The grant was recorded at $0.00 at acquisition (no cash paid at grant). This is an equity award (derivative) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-05; Form 4 filed: 2026-02-09 (filed within the SEC two-business-day window).
• Award: 44,123 shares (derivative/options) acquired at $0.00.
• Vesting: The award vests and becomes exercisable in equal monthly installments over 48 months beginning Feb 5, 2026 (≈ 918 shares vest per month).
• Shares owned after the transaction: Not provided in the supplied filing summary.
• Filing code: A = Grant/Award; no 10b5-1 plan, tax withholding, or cashless-sale details reported in the provided data.

Context

• This was a granted option/award, not an open-market purchase or immediate sale; no immediate cash changed hands. Such grants are a routine form of executive compensation and vest over time to align incentives with company performance and retention.